Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 209-215

  Read, Phillip ^a,b   Lothian, Rebecca ^a   Chronister, Karen ^a,b   Gilliver, Rosie ^a   Kearley, John ^a   Dore, Gregory J ^b,c   van Beek, Ingrid ^a,b  

^a SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antivirals; Harm reduction; Hepatitis C; People who inject drugs; Targeted primary health care; Treatment

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR PLUS SOFOSBUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HOMELESSNESS; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ABUSE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; NONHUMAN; OBSERVATIONAL STUDY; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; THERAPY DELAY; TREATMENT DURATION; TREATMENT WITHDRAWAL; AUSTRALIA; CHRONIC HEPATITIS C; COMMUNITY CARE; COMPLICATION; DRUG USE; MIDDLE AGED; SUBSTANCE ABUSE; VULNERABLE POPULATION;

ADULT; AGED; ANTIVIRAL AGENTS; AUSTRALIA; COHORT STUDIES; COMMUNITY HEALTH SERVICES; DRUG USERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; SUBSTANCE ABUSE, INTRAVENOUS; SUSTAINED VIROLOGIC RESPONSE; VULNERABLE POPULATIONS;

EID: 85020133598     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.05.032     Document Type: Article

References (25)

1. Alavi, M., Raffa, J., Deans, G., Lai, C., Krajden, M., Dore, G., Grebley, J., Continued low uptake of treatment for hepatitis C infection in a large community-based cohort of inner city residents. Liver International 34:8 (2014), 1198–1206.
2. Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., Taylor, L.E., Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 163 (2015), 215–223.
3. Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., De Ledinghen, V., Prospective comparison of transient elastography, fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128:2 (2005), 343–350.
4. Dore, G.J., Law, M., MacDonald, M., Kaldor, J.M., Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology 26:2 (2003), 171–184.
5. Dore, G.J., Feld, J.J., Hepatitis C virus therapeutic development: In pursuit of perfectovir. Clinical Infectious Diseases 60 (2015), 1829–1836.
6. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shilobet, O., Platt, H.L., Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine 165:9 (2016), 625–634.
7. Dore, G.J., Grebely, J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Peng, C.Y., CV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study. 67th annual meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, USA, 2016 Abstract 871.
8. Gilliver, R., Lothian, R., Chronister, K.J., Machin, W., Kearley, J., Dore, G.J., Read, P., An integrated primary health care service is effective at retaining and linking marginalised groups in hepatitis C care: A study of the Kirketon Road Centre, Kings Cross. Australasian Viral Hepatitis Conference 2016, Gold Coast, Australia, 2016 Oral abstract presentation. Available at https://www.eiseverywhere.com/file_uploads/f2c530bea8e951987d9f94565f93d9b7_1130SatRosieGilliver_pdf.pdf (Accessed 26 December 2016).
9. Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., Dore, G.J., Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26 (2015), 1028–1038.
10. Islam, M.M., Topp, L., Day, C.A., Dawson, A., Conigrave, K., The accessibility, acceptability, health impact and cost implications or primary healthcare outlets that target injecting drug users: A narrative synthesis of literature. International Journal of Drug Policy 23:2 (2012), 94–102.
11. Iversen, J., Grebley, J., Topp, L., Wand, H., Dore, G., Maher, L., Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999–2011. Journal of Viral Hepatitis 21:3 (2014), 198–207.
12. Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., Hickman, M., Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58:5 (2013), 1598–1609.
13. Mason, K., Dodd, Z., Guton, M., Tookey, P., Lettner, B., Matelski, J., Powis, J., Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence amongst people witha history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy 47 (2017), 202–208.
14. Mehta, S.H., Genberg, B.L., Astemborski, J., Kavasery, R., Kirk, G.D., Vlahov, D., Thomas, D.L., Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 33:3 (2008), 126–133.
15. Morris, L., Smirnov, A., Kvassay, A., Leslie, E., Kavanagh, R., Alexander, N., Najman, J., The impact of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network. International Journal of Drug Policy 47 (2017), 216–220.
16. Pharmaceutical Benefits Scheme, General statement for drugs for the treatment of hepatitis C. 2016, Australian Government, Department of Health Available at http://www.pbs.gov.au/info/healthpro/explanatory-notes/general-statement-hep-c (Accessed 26 December 2016).
17. Rodgers, C., The Kirketon Road Centre—Improving access to primary care for marginalised populations. Australian Family Physician 41:4 (2012), 245–247.
18. Schitz, A., Moser, S., Marchart, K., Haltmayer, H., Gschwantler, M., Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-threshold drug treatment facility—A new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. American Journal of Gastroenterology, 111, 2016.
19. Strehlow, A.J., Robertson, M.J., Zerger, S., Rongey, C., Arangua, L., Farrell, E., O'Sullivan, A., Gelberg, L., Hepatitis C among clients of health care for the homeless primary care clinics. Journal of Health Care for the Poor and Underserved 23:2 (2012), 811–833.
20. The Kirby Institute, Bloodborne viral and sexually transmitted infections in Australia: Annual Surveillance Report 2016., 2016, The Kirby Institute, UNSW, Australia, Sydney NSW 2052 Available at http://kirby.unsw.edu.au/surveillance/2016-annual-surveillance-report-hiv-viral-hepatitis-stis (Accessed 26 December 2016).
21. The Kirby Institute, Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016., 2016, The Kirby Institute, UNSW, Australia, Sydney NSW 2052 Available at http://kirby.unsw.edu.au/surveillance/hepatitis-b-and-c-australia-annual-surveillance-report-supplement-2016-0 (Accessed 26 December 2016).
22. Topp, L., Iversen, J., Baldry, E., Maher, L., Housing instability among people who inject drugs: Results from the Australian needle and syringe program survey. Journal of Urban Health: Bulletin of the New York Academy of Medicine 90:4 (2012), 699–716.
23. van Beek, I., Case study: accessible primary health care—A foundation to improve health outcomes for people who inject drugs. International Journal of Drug Policy 18 (2007), 329–332.
24. World Health Organization, Declaration of Alma-Ata. International conference on primary health care, Alma-Ata, USSR, 6–12 September 1978, 1978 Available at www.who.int/publications/almaata_declaration_en.pdf (Accessed 26 December 2016).
25. World Health Organization, Global health sector strategy on viral hepatitis 2016–2021. 2016 Available at http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (Accessed 13 March 2017).